Identification of phosphorylated receptors in human tumors and discovery of phospho-PR-regulated pathways (i.e., including HER2, RUNX2, AR, AHR, and PAX2) suggest novel ways to specifically target breast cancer stem cell (CSC) outgrowth as part of durable breast cancer therapies. This evidence concerns the gene ERBB2 and breast carcinoma.